Be the global leader of T cell cancer immunotherapy
Advisory Team
  • Mark M. Davis
    Mark M. Davis
    Director of Stanford Institute for Immunity, Transplantation and Infection
    Member of the American Academy of Sciences, the American Academy of Sciences and Arts, American College of Medicine; and, Fellow, the Royal Society of the United Kingdom

    Dr.Mark M. Davis is the Burt and Marion Avery Family Professor of Immunology atStanford University. Dr. Davis has been an investigator at the Howard HughesMedical Institute since 1987. He is also a member of National Academy ofSciences, American Academy of Arts and Sciences, and National Academy ofMedicine. Since his ground-breaking cloning of T cell antigen receptor (TCR) genesin 1984, Dr. Davis has been a pioneer and leader the field of molecularimmunology. Specifically, by pushing the boundaries of knowledge in multipleareas, such as antigen receptor recognition, thymic selection, and B cellterminal differentiation, his discoveries shaped our understanding of selfversus non-self discrimination, the most fundamental question in adaptiveimmunity. In addition, the Davis lab is the acclaimed source of technologyintegration and innovation. The application of protein chemistry, biophysicsand live cell imaging in Davis lab have made the study of T cell recognition themost advanced and quantitative of any system of cell-cell recognition inbiology. Technologies developed in Davis lab, such as peptide-MHC tetramers,have become standard tools in basic and clinical immunology studies. In 2004,Dr. Davis became the founding director of Stanford Institute for Immunity,Transplantation and Infection and an advocate of human immunology. He thenchanged his lab’s focus away from basic immunology to studies of the humanimmune system. Here, he has also had a tremendous impact, developing moreadvanced ways to monitor immunity and responses clinically, and integratingrepertoire sequencing, single cell genomics and proteomics technologies tochallenge immunological dogma and the power of human work to contribute tobasic immunological principals. His innovations and dedication have opened anew chapter in human immunology and translational medicine.

  • Xiao-Fan Wang
    Xiao-Fan Wang
    Donald and Elizabeth Cooke Professor of Cancer Research at Duke University
    Foreign Members of the Chinese Academy of Science President of the Society of Chinese Bioscientists in America

    Prof. Wang has made important contributionsto cancer-related fields such as cell signal transduction, DNA damage andrepair, and tumor microenvironment. He was the first to clone the TGF-β type IIand type III receptors, which was an important discovery and had profoundimpact on the subsequent research of TGF-β. He also determined severalimportant regulatory factors and mechanisms of the TGF-β pathway, which are criticalto current understanding of the tumor microenvironment. Prof. Wang publishedmore than 20 papers in high profile journals including Cell, Nature,Science, Genes and Development, P.N.A.S.

    Since 2006, he has served as the deputyeditor-in-chief of the Journal of Biological Chemistry. During histenure as editor-in-chief, he introduced dozens of Chinese science andtechnology leaders to advocate for the impact of Chinese scientists to theglobal community. Since 2007, he served as a member of the Overseas ExpertAdvisory Committee of China. In 2010, he has been appointed as a member of thescientific board of the Ministry of Science and Technology and has participatedin many reforms of Chinese science policies. In order to help establishing anacademic evaluation system in China, Prof. Wang organized a team of expertsfrom more than 10 top life science research institutes including ChineseAcademy of Sciences, Tsinghua University, Peking University, ZhejiangUniversity Life and other universities.

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
Introduction to TCRCure
Immune Cell Therapy
Product and Services

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer